Vecchiet J, Dalessandro M, Travasi F, Falasca K, Di Iorio A, Schiavone C, Zingariello P, Di Ilio E, Pizzigallo E, Paganelli R
Section of Infectious Diseases, Department of Medicine and Sciences of Aging, University G d'Annunzio, Chieti, Italy.
Int J Immunopathol Pharmacol. 2003 May-Aug;16(2):157-66. doi: 10.1177/039463200301600210.
Several lines of evidence indicate that a switch of the cytokine pattern from a predominant type 1 (antiviral and cell mediated response) to type 2 (polyclonal humoral immune response) occurs during the course of Human Immunodeficiency Virus-1 (HIV-1) infection, and represents a key event in the progression of immunodeficiency and dysregulated immune activation. We proposed to further investigate this immunological aspect of HIV-1 disease, in naive and in patients treated with Highly Active Antiretroviral Therapy (HAART). The prototypic cytokines chosen were Interleukin (IL)-4 and Interferon-gamma (IFN-gamma), whose in vitro production was determined in mononuclear cell cultures stimulated with different T lymphocyte mitogenic agents (anti-CD3, Phytohaemoagglutin-P -PHA-, E. coli B04/035 Lipopolysaccharide -LPS-). We classified all the patients on the basis of the number of CD4+ lymphocytes and we found a progressive, even if not significant decrease in the baseline production of IFN-gamma with the progression of the immunodeficiency. The mean value of baseline IFN-gamma in the group of patients with CD4+>500 cells/microL was 7.79 +/- 3.1 pg/mL while in the group with CD4+<200 cells/microL it was 4.66 +/- 2.22. We didn't find significant differences in the baseline production of IL-4 in these groups and in IFN-gamma and IL-4 production in LPS-stimulated cultures. We also re-assessed 12 patients after one year's follow-up. They presented a significant increase in IFN-gamma production compared to the first assessment in the LPS-stimulated cultures (baseline IFN-gamma 2.87 +/- 1.17 pg/mL, after 12 months 19.15 +/- 5.19 pg/mL; p= 0.03). In the 12 patients in follow-up IL-4 production showed a decreased in PHA-stimulated cultures with mean values of 16.65 +/- 14.32 pg/mL at baseline and 6.54 +/- 6.54 pg/mL after follow-up. These results highlight the immunorestoring effects of HAART. IL-4 production was lower in the treated subjects compared to the naive ones in PHA-stimulated cultures (mean values: IL-4=13.42 +/- 11.08 pg/mL in the naive patients and 9.75 +/- 65 pg/mL in the treated patients). The IFN-gamma values in anti-CD3 stimulated cultures were also higher in the treated patients, but this increase was not significant.
多项证据表明,在人类免疫缺陷病毒1型(HIV-1)感染过程中,细胞因子模式会从主要的1型(抗病毒和细胞介导反应)转变为2型(多克隆体液免疫反应),这是免疫缺陷进展和免疫激活失调中的一个关键事件。我们提议进一步研究HIV-1疾病在未接受治疗的患者以及接受高效抗逆转录病毒疗法(HAART)治疗的患者中的这一免疫学方面。所选择的典型细胞因子是白细胞介素(IL)-4和干扰素-γ(IFN-γ),其体外产生情况在由不同T淋巴细胞促有丝分裂剂(抗CD3、植物血凝素-P -PHA-、大肠杆菌B04/035脂多糖 -LPS-)刺激的单核细胞培养物中进行测定。我们根据CD4+淋巴细胞数量对所有患者进行分类,发现随着免疫缺陷的进展,IFN-γ的基线产生量逐渐下降,尽管差异不显著。CD4+>500个细胞/微升的患者组中基线IFN-γ的平均值为7.79±3.1皮克/毫升,而CD4+<200个细胞/微升的患者组中该值为4.66±2.22。我们未发现这些组中IL-4的基线产生量以及LPS刺激培养物中IFN-γ和IL-4产生量存在显著差异。我们还对12名患者进行了一年的随访后重新评估。与首次评估相比,他们在LPS刺激培养物中的IFN-γ产生量显著增加(基线IFN-γ为2.87±1.17皮克/毫升,12个月后为19.15±5.19皮克/毫升;p = 0.(此处原文有误,推测应为p = 0.03)。在12名接受随访的患者中,PHA刺激培养物中的IL-4产生量下降,基线平均值为16.65±14.32皮克/毫升,随访后为6.54±6.54皮克/毫升。这些结果突出了HAART的免疫恢复作用。在PHA刺激培养物中,接受治疗的受试者的IL-4产生量低于未接受治疗的受试者(平均值:未接受治疗的患者中IL-4 = 13.42±11.08皮克/毫升,接受治疗的患者中为9.75±65皮克/毫升)。接受治疗的患者在抗CD3刺激培养物中的IFN-γ值也较高,但这种增加不显著。